Open-label or unblinded (moderate): Open-label design

Industry funded (moderate): Industry funding reported

HbA1c improved slightly in both groups, but the between-group difference was small and crossed no clear benefit threshold. This suggests iGlarLixi maintained glycemic control rather than clearly outperforming continued MDI on the primary endpoint.

Body weight fell more with iGlarLixi than with continued MDI. The between-group difference favored iGlarLixi by 4.19 kg over 24 weeks.

BMI decreased more with iGlarLixi than with continued MDI. The between-group difference was 1.49 kg/m2 in favor of the simplification strategy.

Participants who switched to iGlarLixi used much less insulin by the end of treatment. The between-group difference in total daily insulin dose was 28.57 IU in favor of iGlarLixi.

Fasting plasma glucose decreased in both groups, but the between-group difference was not clearly meaningful. This supports similar fasting glucose control with the two strategies.

The paper reports no significant changes in postprandial glucose values between the groups. That suggests the simplification strategy did not clearly improve this endpoint compared with staying on MDI.

Time spent in level 2 hyperglycemia above 13.9 mmol/L decreased more with iGlarLixi than with continued MDI. The between-group difference was 4.9 percentage points in favor of iGlarLixi.

The glycemia risk index improved more with iGlarLixi than with continued MDI, with a between-group difference of 13.6 points in favor of iGlarLixi. This supports a better overall glucose pattern on sensor monitoring.

Treatment satisfaction scores were higher in the iGlarLixi group at the end of treatment, especially for convenience and flexibility. Because these were open-label patient-reported outcomes with incomplete questionnaire return, the evidence is supportive but less certain than the laboratory outcomes.

A lower proportion of study visits included reported hypoglycemia in the iGlarLixi group, but the proportion of participants with at least one hypoglycemia event did not clearly differ. This suggests a possible benefit, but the safety signal was not uniformly positive across all hypoglycemia measures.

Once-daily fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide used to simplify therapy in people previously treated with multiple daily insulin injections.

Positive: 7; Negative: 0; No effect: 3; Mixed: 0

Direction counts recalculated from intervention outcomes due to mismatch with AI-provided counts.

Extracted 10 outcome signals across the study

The primary HbA1c outcome was similar between groups, but several secondary outcomes favored iGlarLixi, especially weight, BMI, insulin dose, and selected CGM metrics, without an obvious major safety penalty.

Direction counts were recalculated from extracted outcomes because the AI-provided totals did not match.

HbA1c ↔ stayed similar between iGlarLixi and MDI over 24 weeks

Mostly intermediate or surrogate outcomes

The between-group difference in HbA1c change was -0.12%, which suggests similar overall glycemic control.

Body weight fell 4.19 kg more with iGlarLixi than with continued MDI.

Total daily insulin dose changed by -28.57 IU in favor of iGlarLixi.

Time spent above 13.9 mmol/L and glycemia risk index both improved more with iGlarLixi.

Novodvorsky P, Thieme L, Lankova I, et al. Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial. Diabetes Obes Metab. 2026;28(3):1817-1825. doi:10.1111/dom.70362

The study was open label, so patient-reported outcomes were more vulnerable to bias.

The trial was conducted in one country and all participants were white.

Most participants were men, which limits how broadly the findings may apply.

In adults with type 2 diabetes using multiple daily injections, switching to once-daily iGlarLixi kept HbA1c about the same over 24 weeks while lowering weight, insulin dose, and some hyperglycemia measures.

Body weight ↓ more with iGlarLixi than with continued MDI

Total daily insulin dose ↓ substantially after switching to iGlarLixi

Marked hyperglycemia time ↓ and glycemia risk index ↓ with iGlarLixi

The ADA Standards of Care give current clinical guidance on glucose-lowering therapy, including when to simplify or intensify treatment and how to individualize therapy for people with type 2 diabetes.

This ADA and EASD consensus report outlines modern treatment pathways for type 2 diabetes and helps frame why simplifying older insulin regimens may be reasonable when newer drug classes are available.

Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

This pragmatic randomized trial tested insulin regimen simplification strategies in type 2 diabetes and provides close context for the current study. It supports the idea that selected patients can reduce regimen complexity without clearly losing glucose control.

Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial

SoliMix offers direct evidence on iGlarLixi in type 2 diabetes and helps place the IDEAL findings in a broader clinical context. It supports the combination as a practical alternative to more burdensome insulin strategies.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial

Includes self-reported outcomes (moderate): Self-reported outcomes used

Limited population scope (moderate): Narrow population scope

Open-label or unblinded study (moderate): Open-label design

Switching from MDI to iGlarLixi kept HbA1c similar and lowered weight

This trial compared switching from multiple daily insulin injections to once-daily iGlarLixi against staying on the same injection regimen. Over 24 weeks, blood sugar control stayed similar in both groups, but the iGlarLixi group lost more weight, used less insulin, and spent less time in marked hyperglycemia.

This study tested treatment simplification in a selected group, not in everyone with type 2 diabetes on insulin. The main glycemic outcome was similar between groups, so the benefit came more from lower treatment burden, lower insulin dose, weight loss, and some sensor-based glucose measures. Because the trial was open label and modest in size, the findings are best used as supportive rather than definitive for all patients.

Switching adults with type 2 diabetes from MDI insulin to once-daily iGlarLixi

These results apply most directly to adults with type 2 diabetes who were already using multiple daily insulin injections, had preserved fasting C-peptide, and were treated in specialist diabetes care. The average participant was older, had long-standing diabetes, and had obesity or overweight.

Switching from MDI to iGlarLixi kept HbA1c similar and lowered weight

John Wiley & Sons Ltd

Resumen

Diseño del Estudio

Intervenciones

Tipo de Estudio

Resultados

Duración y Tamaño

Población del Estudio

Rango de Edad

Sexo

Geografía

Otros Criterios

Comparación con otros Estudios

Referencia de la Revista

Mantente informado. Mantente adelante.